The antimicrobial hygiene product industry is facing a comprehensive tightening of technical benchmarks. In early August, the T/CIAA 008—2026 standard for antimicrobial sanitary pads and period pants was officially released, replacing the 2020 edition. The most significant change is the addition of a 'long-lasting antimicrobial' requirement, which mandates that products retain their antimicrobial efficacy after simulated use—specifically, after contact with bovine serum albumin at 36°C for no less than 8 hours. This means products that only perform well in laboratory tests but fail in real-world conditions will no longer pass muster.
The Industrial Logic Behind the Standard Upgrade
The standard is managed by the Zhongguancun HuiZhi Antimicrobial New Material Industry Technology Innovation Alliance, with drafting contributions from Henan Shulai, Guangdong Institute of Microbiology, SGS, and Jinda Nano Technology. The composition of the drafting units reflects a full industry chain, including finished product brands, testing institutions, and antimicrobial material suppliers. The revision aligns with GB 15979-2024, adjusting definitions, requirements, and test methods, and expanding the product scope to include period pants, responding to the rapid market growth of menstrual pants and sleep shorts.
For upstream suppliers, the upgraded standard implies higher technical barriers. The 'long-lasting antimicrobial' requirement directly challenges the durability of top sheets, absorbent layers, and antimicrobial finishing agents. Traditional treatments using silver ions, chitosan, or quaternary ammonium salts often lose efficacy in bodily fluids. The new standard compels nonwoven and fabric manufacturers to develop more durable antimicrobial technologies, such as microencapsulation or covalent grafting. For companies with technical reserves, this is an opportunity for differentiation; for those relying on low-cost homogeneous products, it may lead to market exit.
Transmission Effects on Procurement and Supply Chains
From a procurement perspective, the new standard will directly influence sourcing strategies for hygiene product brands. Previously, buyers often focused solely on antimicrobial rates of finished products. Now, they must trace the durability of antimicrobial agents under simulated body fluid conditions. This means suppliers of nonwovens, hot-air fabrics, and back sheets must provide more detailed performance data, including test reports on long-lasting efficacy. Buyers should incorporate long-lasting antimicrobial testing as a key criterion during factory audits and sample evaluations, rather than relying solely on factory release tests.
For foreign trade enterprises, although this is a group standard, its technical approach aligns with antimicrobial regulations in the EU and Japan. The EU Biocidal Products Regulation (BPR) and the US EPA's requirements for antimicrobial efficacy validation emphasize simulated real-use conditions. Therefore, the T/CIAA 008—2026 revision provides a technical benchmark for domestic enterprises to align with international standards. Companies that adapt early will have a stronger position in international customer audits.